Speedel (SWX: SPPN) announced today the initiation of a Phase I trial of SPP1148, the most promising compound from a new series of renin inhibitors for the treatment of hypertension and related end-organ disease. The Phase I trial will test the safety and tolerability of single and multiple oral doses in healthy volunteers and first results are expected in Q4 2007. The SPP1100 series is one of several new series of renin inhibitors invented by Speedel Experimenta, the company's late-stage research unit, which was established in 2002.
